Microbix Biosystems (TSX:MBX) has completed a second and final tranche of a private placement, raising gross proceeds of $1.17-million, in addition to $2.33-million from the first tranche.Read More
Microbix Biosystems (TSX:MBX) announced the withdrawal of legal claims, alleging patent infringement, that were filed in Canadian Federal Court against Microbix by ZeptoMetrix in October 2016.Read More
Microbix Biosystems (TSX:MBX) has made its first full-scale shipment of antigen produced using its new bioreactor manufacturing process, following customer validation.Read More
Microbix Biosystems (TSX:MBX) reported record revenue for the fiscal third quarter ended June 30, 2017 of $2.8-million, up 23% from the same quarter a year ago. Net profit was $188,646, compared with $47,953 a year earlier.Read More
Microbix Biosystems (TSX:MBX) agreed to supply an existing long-term customer with an increasing quantity of its viral antigen products over the next five years, with an option to extend that term.Read More
Microbix Biosystems (TSX:MBX) has appointed Cameron Groome as its president and CEO, with Vaughn Embro-Pantalony retiring from those positions but remaining an executive director, working closely with Mr. Groome to ensure a smooth leadership transition.Read More
Microbix Biosystems (TSX:MBX) has consulted with the FDA regarding the company's plans to return its thrombolytic biologic drug, Kinlytic, to the U.S. market.Read More
Microbix Biosystems (TSX:MBX) reported that revenue rose 84% to almost $2-million for the first quarter ended Dec. 31, 2016, from $1.1-million a year earlier.Read More
Microbix Biosystems (TSX:MBX) has signed a distribution agreement with Meridian Life Science, a wholly owned unit of Meridian Bioscience (NASDAQ:VIVO), a fully integrated global diagnostic and life sciences company.Read More
Sales for Microbix Biosystems (TSX:MBX) in the fourth quarter of fiscal 2016 climbed 64% to $3.5-million, representing the highest quarterly revenue ever achieved by the company, from $2.1-million a year earlier.Read More
Microbix Biosystems (TSX:MBX) has arranged a new secured revolving credit facility jointly with Toronto-Dominion Bank and Export Development Canada.Read More
Microbix Biosystems (TSX:MBX) appointed Jim Currie as CFO, succeeding Charles Wallace, who is retiring at the end of the year.
Mr. Currie was most recently CFO of SMTC, a global electronics manufacturing services company. Previously, he was VP of finance at MDS SCIEX, a global leader in life science and analytical technologies.Read More
Microbix Biosystems (TSX:MBX) expects to report revenue in the range of $3.3-million for the fiscal fourth quarter ended Sept. 30, 2016, an increase of 57% from $2.1-million in the year earlier quarter.
Fourth quarter virology revenue is expected to be in the range of $3.3-million, up 106%, compared with $1.6-million in the fourth quarter of fiscal 2015.Read More
Microbix Biosystems (TSX:MBX) expects a strong performance over the rest of the fiscal year based on indicated customer demand, leading the company to project record sales for the current fiscal year, ending Sept. 30.
“Thus far, sales for the second quarter are in line with such full-year expectations,” Vaughn Embro-Pantalony, president and CEO, said in the first quarter earnings report.Read More